Domínguez-Muñoz J Enrique, Iglesias-García Julio
Department of Gastroenterology and Foundation for Research in Digestive Diseases (FIENAD), University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
JOP. 2010 Mar 5;11(2):158-62.
Malnutrition secondary to pancreatic exocrine insufficiency plays a prognostic role in chronic pancreatitis. Enzyme substitution therapy is generally prescribed to avoid diarrhea and weight loss, although it is unknown whether this is associated with normal absorption of nutrients and a normal nutritional status.
We aimed to evaluate whether an adequate clinical response to enzyme therapy can be used to predict a normal nutritional status in patients with chronic pancreatitis.
Thirty-one consecutive patients (25 males, 6 females; mean age 52 years,) with severe chronic pancreatitis and steatorrhea were enrolled in the study.
Enzyme substitution therapy was indicated in cases with severe steatorrhea (more than 15 g/day), diarrhea and/or weight loss. Therapy was optimized in individual patients to obtain complete symptom relief.
A nutritional evaluation including body mass index and serum levels of retinol-binding protein, prealbumin and transferrin was carried out.
Ten out of ten patients with asymptomatic steatorrhea, who did not fulfill the criteria for enzyme substitution therapy, and 11 out of 21 patients (52.4%) with symptomatic or more severe steatorrhea, who were under enzyme substitution therapy, showed a deficient nutritional status.
An appropriate clinical response to enzyme substitution therapy does not allow the prediction of a normal nutritional status in patients with chronic pancreatitis.
胰腺外分泌功能不全继发的营养不良在慢性胰腺炎中具有预后作用。通常会开具酶替代疗法以避免腹泻和体重减轻,尽管尚不清楚这是否与营养物质的正常吸收和正常营养状况相关。
我们旨在评估对酶疗法的充分临床反应是否可用于预测慢性胰腺炎患者的正常营养状况。
连续纳入31例重度慢性胰腺炎和脂肪泻患者(25例男性,6例女性;平均年龄52岁)进行研究。
对于重度脂肪泻(超过15克/天)、腹泻和/或体重减轻的患者,采用酶替代疗法。对个体患者的治疗进行优化以实现症状完全缓解。
进行包括体重指数以及视黄醇结合蛋白、前白蛋白和转铁蛋白血清水平的营养评估。
10例无症状脂肪泻且不符合酶替代疗法标准的患者中,以及21例接受酶替代疗法的有症状或更严重脂肪泻患者中的11例(52.4%),营养状况不佳。
对酶替代疗法的适当临床反应无法预测慢性胰腺炎患者的正常营养状况。